How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8097"
  ["article_id"]=>
  string(4) "8097"
  [1]=>
  string(62) "New study on COVID-19 estimates 5.1 days for incubation period"
  ["article_title"]=>
  string(62) "New study on COVID-19 estimates 5.1 days for incubation period"
  [2]=>
  string(150) "An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory illness COVID-19 yielded an est"
  ["short_description"]=>
  string(150) "An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory illness COVID-19 yielded an est"
  [3]=>
  string(236) "An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory illness COVID-19 yielded an estimate of 5.1 days for the median disease incubation period, according to a new study. "
  ["description"]=>
  string(236) "An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory illness COVID-19 yielded an estimate of 5.1 days for the median disease incubation period, according to a new study. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200310164744.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200310164744.htm"
  [15]=>
  string(19) "2020-03-11 04:47:44"
  ["add_date"]=>
  string(19) "2020-03-11 04:47:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:52"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:52"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

New study on COVID-19 estimates 5.1 days for incubation period

An analysis of publicly available data on infections from the new coronavirus, SARS-CoV-2, that causes the respiratory i

array(40) {
  [0]=>
  string(4) "8061"
  ["article_id"]=>
  string(4) "8061"
  [1]=>
  string(42) "22nd Century Group Adds to Leadership Team"
  ["article_title"]=>
  string(42) "22nd Century Group Adds to Leadership Team"
  [2]=>
  string(150) "New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engag"
  ["short_description"]=>
  string(150) "New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engag"
  [3]=>
  string(322) "New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement 
New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement
"
  ["description"]=>
  string(322) "New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement 
New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(113) "http://www.globenewswire.com/news-release/2020/03/10/1998362/0/en/22nd-Century-Group-Adds-to-Leadership-Team.html"
  ["blog_url"]=>
  string(113) "http://www.globenewswire.com/news-release/2020/03/10/1998362/0/en/22nd-Century-Group-Adds-to-Leadership-Team.html"
  [15]=>
  string(19) "2020-03-11 04:15:00"
  ["add_date"]=>
  string(19) "2020-03-11 04:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:34"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

22nd Century Group Adds to Leadership Team

New Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Effo

array(40) {
  [0]=>
  string(4) "8062"
  ["article_id"]=>
  string(4) "8062"
  [1]=>
  string(91) "Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results"
  ["article_title"]=>
  string(91) "Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Results"
  [2]=>
  string(150) "CAMBRIDGE, Mass., March  10, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its "
  ["short_description"]=>
  string(150) "CAMBRIDGE, Mass., March  10, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its "
  [3]=>
  string(298) "
CAMBRIDGE, Mass., March  10, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2019 financial results.
"
  ["description"]=>
  string(298) "
CAMBRIDGE, Mass., March  10, 2020  (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter and full-year 2019 financial results.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(162) "http://www.globenewswire.com/news-release/2020/03/10/1998357/0/en/Constellation-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  ["blog_url"]=>
  string(162) "http://www.globenewswire.com/news-release/2020/03/10/1998357/0/en/Constellation-Pharmaceuticals-Announces-Fourth-Quarter-and-Full-Year-2019-Financial-Results.html"
  [15]=>
  string(19) "2020-03-11 04:12:00"
  ["add_date"]=>
  string(19) "2020-03-11 04:12:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:34"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2019 Financial Result

CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage bio

array(40) {
  [0]=>
  string(4) "8155"
  ["article_id"]=>
  string(4) "8155"
  [1]=>
  string(70) "FDA Suspends Inspections Outside of the US Due to Coronavirus Outbreak"
  ["article_title"]=>
  string(70) "FDA Suspends Inspections Outside of the US Due to Coronavirus Outbreak"
  [2]=>
  string(156) "&#nlFDA is suspending its inspections outside of the US through April in response to the coronavirus (COVID-19) pandemic.&#nlInspections outside of the U.S."
  ["short_description"]=>
  string(156) "&#nlFDA is suspending its inspections outside of the US through April in response to the coronavirus (COVID-19) pandemic.&#nlInspections outside of the U.S."
  [3]=>
  string(2798) "&#nl
FDA is suspending its inspections outside of the US through April in response to the coronavirus (COVID-19) pandemic.
&#nl
Inspections outside of the U.S. would be deemed “mission-critical” and would be considered on a case-by-case basis. The measure would be effective immediately.
&#nl
In a release, FDA Commissioner Stephen Hahn, MD said, “We are aware of how this action may impact other FDA responsibilities, including product application reviews. We will be vigilant and monitor the situation very closely and will try to mitigate potential impacts from this outbreak in lockstep with the whole of the federal government. We stand ready to resume foreign inspections as soon as feasible.”
&#nl
FDA said it based this decision on several different factors, including State Department Level 4 travel advisories in which travel is prohibited for U.S. government employees; Centers for Disease Control and Prevention travel recommendations; access restrictions being imposed on foreign visitors by certain countries; guidance from the Office of Personnel Management; and the importance of the health and safety of its employees.
&#nl
The agency has taken measures and worked to get out in front of coronavirus. In late January, FDA laid out a multi-pronged strategy to handle any potential coronavirus outbreaks. Early last month,  FDA granted EUA for the Centers for Disease Control and Prevention’s Coronavirus detection test. Up until then, the Prevention’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been used at CDC laboratories.
&#nl
FDA’s most recent measure comes at a time when President Trump is working on two different pieces to handle the coronavirus pandemic. Last week, Trump signed an $8.3 billion spending plan to help combat the coronavirus. Specifically, the bill would fund vaccine development efforts to help assist state and local government in their response, according to a report from WSJ.
&#nl
The president is also proposing a payroll tax break to deal with the financial fallout related to coronavirus.
&#nl
To date, there have been about 773 coronavirus cases in the U.S. with 28 dead and 15 recovering, according to statistics from worldometer.
"
  ["description"]=>
  string(2798) "&#nl
FDA is suspending its inspections outside of the US through April in response to the coronavirus (COVID-19) pandemic.
&#nl
Inspections outside of the U.S. would be deemed “mission-critical” and would be considered on a case-by-case basis. The measure would be effective immediately.
&#nl
In a release, FDA Commissioner Stephen Hahn, MD said, “We are aware of how this action may impact other FDA responsibilities, including product application reviews. We will be vigilant and monitor the situation very closely and will try to mitigate potential impacts from this outbreak in lockstep with the whole of the federal government. We stand ready to resume foreign inspections as soon as feasible.”
&#nl
FDA said it based this decision on several different factors, including State Department Level 4 travel advisories in which travel is prohibited for U.S. government employees; Centers for Disease Control and Prevention travel recommendations; access restrictions being imposed on foreign visitors by certain countries; guidance from the Office of Personnel Management; and the importance of the health and safety of its employees.
&#nl
The agency has taken measures and worked to get out in front of coronavirus. In late January, FDA laid out a multi-pronged strategy to handle any potential coronavirus outbreaks. Early last month,  FDA granted EUA for the Centers for Disease Control and Prevention’s Coronavirus detection test. Up until then, the Prevention’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been used at CDC laboratories.
&#nl
FDA’s most recent measure comes at a time when President Trump is working on two different pieces to handle the coronavirus pandemic. Last week, Trump signed an $8.3 billion spending plan to help combat the coronavirus. Specifically, the bill would fund vaccine development efforts to help assist state and local government in their response, according to a report from WSJ.
&#nl
The president is also proposing a payroll tax break to deal with the financial fallout related to coronavirus.
&#nl
To date, there have been about 773 coronavirus cases in the U.S. with 28 dead and 15 recovering, according to statistics from worldometer.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(87) "https://www.mddionline.com/fda-suspends-inspections-outside-us-due-coronavirus-outbreak"
  ["blog_url"]=>
  string(87) "https://www.mddionline.com/fda-suspends-inspections-outside-us-due-coronavirus-outbreak"
  [15]=>
  string(19) "2020-03-11 04:08:54"
  ["add_date"]=>
  string(19) "2020-03-11 04:08:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:24:03"
  ["create_at"]=>
  string(19) "2020-03-11 16:24:03"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Suspends Inspections Outside of the US Due to Coronavirus Outbreak

 

array(40) {
  [0]=>
  string(4) "8063"
  ["article_id"]=>
  string(4) "8063"
  [1]=>
  string(86) "CV SCIENCES, INC. RESCHEDULES FULL YEAR 2019 RESULTS CONFERENCE CALL TO MARCH 16, 2020"
  ["article_title"]=>
  string(86) "CV SCIENCES, INC. RESCHEDULES FULL YEAR 2019 RESULTS CONFERENCE CALL TO MARCH 16, 2020"
  [2]=>
  string(190) "SAN DIEGO, March  10, 2020  (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”)"
  ["short_description"]=>
  string(190) "SAN DIEGO, March  10, 2020  (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”)"
  [3]=>
  string(1025) "
SAN DIEGO, March  10, 2020  (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will now release financial results for the year ended December 31, 2019, after the stock market closes on Monday, March 16, 2020. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The Company is rescheduling the timing of its full year 2019 financial results conference call to provide additional time to complete the finalization of its fiscal 2019 income tax provision.
"
  ["description"]=>
  string(1025) "
SAN DIEGO, March  10, 2020  (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will now release financial results for the year ended December 31, 2019, after the stock market closes on Monday, March 16, 2020. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The Company is rescheduling the timing of its full year 2019 financial results conference call to provide additional time to complete the finalization of its fiscal 2019 income tax provision.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(154) "http://www.globenewswire.com/news-release/2020/03/10/1998352/0/en/CV-SCIENCES-INC-RESCHEDULES-FULL-YEAR-2019-RESULTS-CONFERENCE-CALL-TO-MARCH-16-2020.html"
  ["blog_url"]=>
  string(154) "http://www.globenewswire.com/news-release/2020/03/10/1998352/0/en/CV-SCIENCES-INC-RESCHEDULES-FULL-YEAR-2019-RESULTS-CONFERENCE-CALL-TO-MARCH-16-2020.html"
  [15]=>
  string(19) "2020-03-11 04:05:00"
  ["add_date"]=>
  string(19) "2020-03-11 04:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:34"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

CV SCIENCES, INC. RESCHEDULES FULL YEAR 2019 RESULTS CONFERENCE CALL TO MARCH 16, 2020

SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- 

array(40) {
  [0]=>
  string(4) "8201"
  ["article_id"]=>
  string(4) "8201"
  [1]=>
  string(105) "HIMSSCast: What providers, payers and tech developers should know about sweeping new patient access rules"
  ["article_title"]=>
  string(105) "HIMSSCast: What providers, payers and tech developers should know about sweeping new patient access rules"
  [2]=>
  string(150) "Healthcare IT News Editor Mike Miliard, Healthcare Finance News Senior Editor Susan Morse and MobiHealthNews Associate Editor Dave Muoio delve into ON"
  ["short_description"]=>
  string(150) "Healthcare IT News Editor Mike Miliard, Healthcare Finance News Senior Editor Susan Morse and MobiHealthNews Associate Editor Dave Muoio delve into ON"
  [3]=>
  string(241) "Healthcare IT News Editor Mike Miliard, Healthcare Finance News Senior Editor Susan Morse and MobiHealthNews Associate Editor Dave Muoio delve into ONC's and CMS' new rules, how people are reacting and what might happen next. &#nl"
  ["description"]=>
  string(241) "Healthcare IT News Editor Mike Miliard, Healthcare Finance News Senior Editor Susan Morse and MobiHealthNews Associate Editor Dave Muoio delve into ONC's and CMS' new rules, how people are reacting and what might happen next. &#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(130) "https://www.healthcareitnews.com/news/north-america/himsscast-what-providers-payers-and-tech-developers-should-know-about-sweeping"
  ["blog_url"]=>
  string(130) "https://www.healthcareitnews.com/news/north-america/himsscast-what-providers-payers-and-tech-developers-should-know-about-sweeping"
  [15]=>
  string(19) "2020-03-11 04:03:42"
  ["add_date"]=>
  string(19) "2020-03-11 04:03:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:24:14"
  ["create_at"]=>
  string(19) "2020-03-11 16:24:14"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

HIMSSCast: What providers, payers and tech developers should know about sweeping new patie

Healthcare IT News Editor Mike Miliard, Healthcare Finance News Senior Editor Susan Morse and MobiHealthNews Associate E

array(40) {
  [0]=>
  string(4) "7982"
  ["article_id"]=>
  string(4) "7982"
  [1]=>
  string(67) "Ofev Approved for Chronic Fibrosing ILDs With Progressive Phenotype"
  ["article_title"]=>
  string(67) "Ofev Approved for Chronic Fibrosing ILDs With Progressive Phenotype"
  [2]=>
  string(150) "TUESDAY, March 10, 2020 -- Ofev (nintedanib) oral capsules have received the first approval for the treatment of patients with chronic fibrosing inter"
  ["short_description"]=>
  string(150) "TUESDAY, March 10, 2020 -- Ofev (nintedanib) oral capsules have received the first approval for the treatment of patients with chronic fibrosing inter"
  [3]=>
  string(249) "TUESDAY, March 10, 2020 -- Ofev (nintedanib) oral capsules have received the first approval for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, the U.S. Food and Drug Administration..."
  ["description"]=>
  string(249) "TUESDAY, March 10, 2020 -- Ofev (nintedanib) oral capsules have received the first approval for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, the U.S. Food and Drug Administration..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(207) "https://www.drugs.com/news/ofev-approved-chronic-fibrosing-ilds-progressive-phenotype-88855.html?utm_source=ddc&utm_medium=rss&utm_campaign=Ofev+Approved+for+Chronic+Fibrosing+ILDs+With+Progressive+Phenotype"
  ["blog_url"]=>
  string(207) "https://www.drugs.com/news/ofev-approved-chronic-fibrosing-ilds-progressive-phenotype-88855.html?utm_source=ddc&utm_medium=rss&utm_campaign=Ofev+Approved+for+Chronic+Fibrosing+ILDs+With+Progressive+Phenotype"
  [15]=>
  string(19) "2020-03-11 03:03:51"
  ["add_date"]=>
  string(19) "2020-03-11 03:03:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:18:16"
  ["create_at"]=>
  string(19) "2020-03-11 16:18:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Ofev Approved for Chronic Fibrosing ILDs With Progressive Phenotype

TUESDAY, March 10, 2020 -- Ofev (nintedanib) oral capsules have received the first approval for the treatment of patient

array(40) {
  [0]=>
  string(4) "7999"
  ["article_id"]=>
  string(4) "7999"
  [1]=>
  string(61) "Romosozumab Added to Guideline for Management of Osteoporosis"
  ["article_title"]=>
  string(61) "Romosozumab Added to Guideline for Management of Osteoporosis"
  [2]=>
  string(150) "TUESDAY, March 10, 2020 -- In an Endocrine Society guideline update, published online in the March issue of the Journal of Clinical Endocrinology &"
  ["short_description"]=>
  string(150) "TUESDAY, March 10, 2020 -- In an Endocrine Society guideline update, published online in the March issue of the Journal of Clinical Endocrinology &"
  [3]=>
  string(246) "TUESDAY, March 10, 2020 -- In an Endocrine Society guideline update, published online in the March issue of the Journal of Clinical Endocrinology & Metabolism, recommendations are presented for the use of romosozumab in the pharmacological..."
  ["description"]=>
  string(246) "TUESDAY, March 10, 2020 -- In an Endocrine Society guideline update, published online in the March issue of the Journal of Clinical Endocrinology & Metabolism, recommendations are presented for the use of romosozumab in the pharmacological..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(194) "https://www.drugs.com/news/romosozumab-added-guideline-management-osteoporosis-88856.html?utm_source=ddc&utm_medium=rss&utm_campaign=Romosozumab+Added+to+Guideline+for+Management+of+Osteoporosis"
  ["blog_url"]=>
  string(194) "https://www.drugs.com/news/romosozumab-added-guideline-management-osteoporosis-88856.html?utm_source=ddc&utm_medium=rss&utm_campaign=Romosozumab+Added+to+Guideline+for+Management+of+Osteoporosis"
  [15]=>
  string(19) "2020-03-11 03:00:59"
  ["add_date"]=>
  string(19) "2020-03-11 03:00:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:18:16"
  ["create_at"]=>
  string(19) "2020-03-11 16:18:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Romosozumab Added to Guideline for Management of Osteoporosis

TUESDAY, March 10, 2020 -- In an Endocrine Society guideline update, published online in the March issue of the Journal 

array(40) {
  [0]=>
  string(4) "8000"
  ["article_id"]=>
  string(4) "8000"
  [1]=>
  string(53) "Acute Appendicitis Incidence Not Randomly Distributed"
  ["article_title"]=>
  string(53) "Acute Appendicitis Incidence Not Randomly Distributed"
  [2]=>
  string(150) "TUESDAY, March 10, 2020 -- Socioeconomic status and other geographically defined factors are associated with incidence of acute appendicitis (AA), acc"
  ["short_description"]=>
  string(150) "TUESDAY, March 10, 2020 -- Socioeconomic status and other geographically defined factors are associated with incidence of acute appendicitis (AA), acc"
  [3]=>
  string(246) "TUESDAY, March 10, 2020 -- Socioeconomic status and other geographically defined factors are associated with incidence of acute appendicitis (AA), according to a study published online March 4 in JAMA Surgery.&#nlReece A. Golz, from the Boston..."
  ["description"]=>
  string(246) "TUESDAY, March 10, 2020 -- Socioeconomic status and other geographically defined factors are associated with incidence of acute appendicitis (AA), according to a study published online March 4 in JAMA Surgery.&#nlReece A. Golz, from the Boston..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(188) "https://www.drugs.com/news/acute-appendicitis-incidence-not-randomly-distributed-88857.html?utm_source=ddc&utm_medium=rss&utm_campaign=Acute+Appendicitis+Incidence+Not+Randomly+Distributed"
  ["blog_url"]=>
  string(188) "https://www.drugs.com/news/acute-appendicitis-incidence-not-randomly-distributed-88857.html?utm_source=ddc&utm_medium=rss&utm_campaign=Acute+Appendicitis+Incidence+Not+Randomly+Distributed"
  [15]=>
  string(19) "2020-03-11 03:00:53"
  ["add_date"]=>
  string(19) "2020-03-11 03:00:53"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:18:16"
  ["create_at"]=>
  string(19) "2020-03-11 16:18:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Acute Appendicitis Incidence Not Randomly Distributed

TUESDAY, March 10, 2020 -- Socioeconomic status and other geographically defined factors are associated with incidence o

array(40) {
  [0]=>
  string(4) "8156"
  ["article_id"]=>
  string(4) "8156"
  [1]=>
  string(44) "More Tests on the Way as Coronavirus Spreads"
  ["article_title"]=>
  string(44) "More Tests on the Way as Coronavirus Spreads"
  [2]=>
  string(153) "&#nlAs the coronavirus continues to spread, companies are ramping up efforts to develop diagnostics. The latest diagnostic comes from CerTest Biotec and "
  ["short_description"]=>
  string(153) "&#nlAs the coronavirus continues to spread, companies are ramping up efforts to develop diagnostics. The latest diagnostic comes from CerTest Biotec and "
  [3]=>
  string(3210) "&#nl
As the coronavirus continues to spread, companies are ramping up efforts to develop diagnostics. The latest diagnostic comes from CerTest Biotec and Franklin Lakes, NJ-based Becton Dickinson and Company (BD). The duo announced Tuesday the VIASURE SARS-CoV-2 Real-Time Polymerase Chain Reaction (PCR) Detection Kit had been adapted for the BD Max System and won CE mark for use in Europe.
&#nl
In a release, the companies said the VIASURE SARS-CoV-2 Real-Time PCR Detection Kit is a real-time reverse transcriptase PCR assay for use on the fully automated BD Max System. It detects SARS-CoV-2 in clinical samples by amplification of a fragment of the S gene of the virus.
&#nl
RNA is extracted, amplified using RT-PCR and detected using fluorescent reporter dye probes specific to SARS-CoV-2. This VIASURE kit contains in each well all the components necessary for real-time PCR assay in a stabilized format, as well as an internal control to monitor PCR inhibition, according to the release.
&#nl
“The CerTest-developed kit will bring rapid COVID-19 diagnostic capabilities to many laboratories across Europe which desperately need the ability to quickly identify COVID-19 patients so that proper protocols for infection prevention can be instituted,” Nelson Fernandes, managing director of CerTest BioTec, said in a release.
&#nl
Zaragoza, Spain-based, CerTest Biotec and BD’s offering comes on the heels of several announcements in recent weeks on the availability of diagnostics aimed at detecting the coronavirus.
&#nl
Qiagen, which is in the process of being acquired by Thermo Fisher Scientific for $11.5 billion, announced in late February it had shipped its newly developed QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China. The Venlo, Netherlands-based company said it also sent the test kit to public health institutions in other regions, including Europe, South-East Asia, and the Middle East.
&#nl
Last week, Quest Diagnostics said it was launching its COVID-19 test service in the U.S. that aids in the presumptive detection of nucleic acid in respiratory specimens. Laboratory Corporation of America Holdings (LabCorp) announced the availability of its 2019 Novel Coronavirus (COVID-19), NAA test. The Burlington, NC-based company said the test can only be ordered by physicians and other authorized healthcare providers anywhere in the U.S.
&#nl
Salt Lake City, UT-based Co-Diagnostics has been in the spotlight since the eruption of the coronavirus and received CE mark for the Logix Smart COVID-19 Test in late February.
&#nl
 
"
  ["description"]=>
  string(3210) "&#nl
As the coronavirus continues to spread, companies are ramping up efforts to develop diagnostics. The latest diagnostic comes from CerTest Biotec and Franklin Lakes, NJ-based Becton Dickinson and Company (BD). The duo announced Tuesday the VIASURE SARS-CoV-2 Real-Time Polymerase Chain Reaction (PCR) Detection Kit had been adapted for the BD Max System and won CE mark for use in Europe.
&#nl
In a release, the companies said the VIASURE SARS-CoV-2 Real-Time PCR Detection Kit is a real-time reverse transcriptase PCR assay for use on the fully automated BD Max System. It detects SARS-CoV-2 in clinical samples by amplification of a fragment of the S gene of the virus.
&#nl
RNA is extracted, amplified using RT-PCR and detected using fluorescent reporter dye probes specific to SARS-CoV-2. This VIASURE kit contains in each well all the components necessary for real-time PCR assay in a stabilized format, as well as an internal control to monitor PCR inhibition, according to the release.
&#nl
“The CerTest-developed kit will bring rapid COVID-19 diagnostic capabilities to many laboratories across Europe which desperately need the ability to quickly identify COVID-19 patients so that proper protocols for infection prevention can be instituted,” Nelson Fernandes, managing director of CerTest BioTec, said in a release.
&#nl
Zaragoza, Spain-based, CerTest Biotec and BD’s offering comes on the heels of several announcements in recent weeks on the availability of diagnostics aimed at detecting the coronavirus.
&#nl
Qiagen, which is in the process of being acquired by Thermo Fisher Scientific for $11.5 billion, announced in late February it had shipped its newly developed QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China. The Venlo, Netherlands-based company said it also sent the test kit to public health institutions in other regions, including Europe, South-East Asia, and the Middle East.
&#nl
Last week, Quest Diagnostics said it was launching its COVID-19 test service in the U.S. that aids in the presumptive detection of nucleic acid in respiratory specimens. Laboratory Corporation of America Holdings (LabCorp) announced the availability of its 2019 Novel Coronavirus (COVID-19), NAA test. The Burlington, NC-based company said the test can only be ordered by physicians and other authorized healthcare providers anywhere in the U.S.
&#nl
Salt Lake City, UT-based Co-Diagnostics has been in the spotlight since the eruption of the coronavirus and received CE mark for the Logix Smart COVID-19 Test in late February.
&#nl
 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(61) "https://www.mddionline.com/more-tests-way-coronavirus-spreads"
  ["blog_url"]=>
  string(61) "https://www.mddionline.com/more-tests-way-coronavirus-spreads"
  [15]=>
  string(19) "2020-03-11 01:58:52"
  ["add_date"]=>
  string(19) "2020-03-11 01:58:52"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:24:03"
  ["create_at"]=>
  string(19) "2020-03-11 16:24:03"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

More Tests on the Way as Coronavirus Spreads

 

array(40) {
  [0]=>
  string(4) "8139"
  ["article_id"]=>
  string(4) "8139"
  [1]=>
  string(68) "Genmab Taps Bristol Myers Veteran Mancini as Chief Operating Officer"
  ["article_title"]=>
  string(68) "Genmab Taps Bristol Myers Veteran Mancini as Chief Operating Officer"
  [2]=>
  string(150) "Genmab (NASDAQ: GMAB) has appointed Anthony Mancini to serve as executive vice president and chief operating officer. Mancini is joining Copenhagen, D"
  ["short_description"]=>
  string(150) "Genmab (NASDAQ: GMAB) has appointed Anthony Mancini to serve as executive vice president and chief operating officer. Mancini is joining Copenhagen, D"
  [3]=>
  string(351) "Genmab (NASDAQ: GMAB) has appointed Anthony Mancini to serve as executive vice president and chief operating officer. Mancini is joining Copenhagen, Denmark-based Genmab from Bristol Myers Squibb (NYSE: BMY), where he is senior vice president and head of US innovative medicines. When he starts at Genmab on March 23, he will be based in New […]"
  ["description"]=>
  string(351) "Genmab (NASDAQ: GMAB) has appointed Anthony Mancini to serve as executive vice president and chief operating officer. Mancini is joining Copenhagen, Denmark-based Genmab from Bristol Myers Squibb (NYSE: BMY), where he is senior vice president and head of US innovative medicines. When he starts at Genmab on March 23, he will be based in New […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(109) "https://xconomy.com/new-york/2020/03/10/genmab-taps-bristol-myers-veteran-mancini-as-chief-operating-officer/"
  ["blog_url"]=>
  string(109) "https://xconomy.com/new-york/2020/03/10/genmab-taps-bristol-myers-veteran-mancini-as-chief-operating-officer/"
  [15]=>
  string(19) "2020-03-11 01:20:21"
  ["add_date"]=>
  string(19) "2020-03-11 01:20:21"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:57"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Genmab Taps Bristol Myers Veteran Mancini as Chief Operating Officer

Genmab (NASDAQ: GMAB) has appointed Anthony Mancini to serve as executive vice president and chief operating officer. Ma

array(40) {
  [0]=>
  string(4) "8260"
  ["article_id"]=>
  string(4) "8260"
  [1]=>
  string(71) "DolCas tackles liver and vascular health with botanical extracts: Study"
  ["article_title"]=>
  string(71) "DolCas tackles liver and vascular health with botanical extracts: Study"
  [2]=>
  string(109) "A new clinical study suggests branded botanical ingredient  Bergacyn is effective in providing liver support."
  ["short_description"]=>
  string(109) "A new clinical study suggests branded botanical ingredient  Bergacyn is effective in providing liver support."
  [3]=>
  string(109) "A new clinical study suggests branded botanical ingredient  Bergacyn is effective in providing liver support."
  ["description"]=>
  string(109) "A new clinical study suggests branded botanical ingredient  Bergacyn is effective in providing liver support."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(172) "https://www.nutraingredients-usa.com/Article/2020/03/10/DolCas-tackles-liver-and-vascular-health-with-botanical-extracts?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(172) "https://www.nutraingredients-usa.com/Article/2020/03/10/DolCas-tackles-liver-and-vascular-health-with-botanical-extracts?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-11 01:11:00"
  ["add_date"]=>
  string(19) "2020-03-11 01:11:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:08"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

DolCas tackles liver and vascular health with botanical extracts: Study

A new clinical study suggests branded botanical ingredient Bergacyn is effective in providing liver support.